ClinicalTrials.gg
CompletedNCT03025035Updated Oct 28, 2026Results posted

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

A Phase 2 interventional study of Pembrolizumab and Olaparib in Breast Cancer, sponsored by Yuan Yuan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Yuan Yuan · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Updated Oct 28, 2026Posted results revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies testing pembrolizumab in Breast Neoplasms — 22 open to participants now, 45 under way, 8 of them phase 3. pembrolizumab · Breast Neoplasms.

Enrollment
76th of 85
14 · median 44
Started
2017
with 15 others
Phase 2
56 of 85
13 open now
Registered
22nd of 85
by date

Among the 85 studies testing pembrolizumab in Breast Neoplasms, this one is the 76th largest by enrollment, is one of 16 that started in 2017, is one of 56 in phase 2, and was the 22nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 85 studies testing pembrolizumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies testing pembrolizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) in combination with Olaparib (PARP inhibitor) in advanced BRCA-mutated or Homology-directed repair (HDR)-defect breast cancer.

Read the detailed description

There are two BRCA genes, BRCA1 and BRCA2, and they play a role in protecting cells from cancer. HDR-defect is another type of gene mutation that can contribute to development and progression of cancer. If one of these genes is mutated, cells may rapidly change and divide, which can lead to cancer. Pembrolizumab is a drug that works with the immune system to target the tumor (immunotherapy). The investigators want to know if combining pembrolizumab and Olaparib therapy will be able to reduce the size and amount of cancer cells with fewer side effects than standard treatment by targeting the tumor. This research study is designed to test the investigational use of pembrolizumab and Olaparib in breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • BRCA-mutation
  • Immune checkpoint inhibition
  • Immunotherapy
  • Advanced BRCA-mutated breast cancer
  • HDR-defect
  • PARP inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing and able to provide written /assent for the trial
  • Be ≥18 years of age on day of signing informed consent
  • Advanced BRCA-mutated and/or HDR-defect breast cancer progressing on or after prior therapy for disease or locally advanced disease; Prior therapy is defined as follows: for triple negative breast cancer - progressing after at least 1 line of any prior chemotherapy; for positive disease must have progressed after at least two HER2 directed therapies in the metastatic setting including ado-trastuzumab emtansine (T-DM1); for hormone receptor positive disease (ER, PR, or both) must have progressed after a CDK4/CDK6 inhibitor plus hormonal therapy. Patients with progression within 12 months from previous or adjuvant treatment could be enrolled in the study as therapy in metastatic setting.
  • by 1.1, with at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements. Patients with non-measurable bone metastases in addition to measurable disease are eligible; however patients with non-measurable bone disease as the only site(s) of disease are not eligible.
  • 0 or 1
  • Documented BRCA deleterious germline or somatic mutation and/or HDR-defect.
  • FFPE tumor tissue available for analysis
  • Adequate organ function
  • Female subjects: or evidence of non-childbearing status for women of : negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1. Postmenopausal is defined as:

    1. Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50
    2. radiation-induced oophorectomy with last menses >1 year ago
    3. chemotherapy-induced menopause with >1 year interval since last menses
    4. surgical sterilization (bilateral oophorectomy or hysterectomy)
  • Women of childbearing potential and their partners, who are sexually active, must agree to the use of TWO highly effective forms of in combination. This should be started from the signing of the informed consent and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse.
  • Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential
  • Patients must have a ≥ 16 weeks

Exclusion criteria

Exclusion Criteria:

  • Is currently participating or has participated in a study of agent or using an investigational device with 30 days of the first dose of pembrolizumab.

    1. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study Day 1.
    2. Subjects must have recovered (i.e., ≤ Grade 1 or at baseline) from any adverse events due to a previously administered agent. Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
    3. If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  • Is receiving systemic therapy within three days prior to the first dose of pembrolizumab or receiving any other form of medication
  • Is expected to require any other form of systemic or localized antineoplastic therapy while on trial.

    1. Subjects with ER+/PR+ disease may be given endocrine therapy.
    2. Subjects with + disease will be required to discontinue trastuzumab (Herceptin).
  • Has participated in another MK03475 trial.

    a. Note: Patients with or without prior PARP-inhibitor exposure may be included.

  • Concomitant use of known strong inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required prior to starting olaparib is 2 weeks.
  • Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  • Has known to pembrolizumab or any of its
  • Has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  • Has known history of prior malignancy except if the patient has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis. Subjects with previously treated may participate provided they are stable (without evidence of progression by MRI for at least four weeks prior to the first dose of pembrolizumab and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are using no steroids for at least three days prior to study medication.
  • Has evidence of interstitial lung disease or active, non-infectious pneumonitis
  • Has active tuberculosis
  • Resting indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, prolongation >500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.
  • Persistent toxicities (>Common Terminology Criteria for Adverse Event () grade 2) caused by previous cancer therapy, excluding alopecia.
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
  • Has received a or live-attenuated vaccine within 30 days prior to the first dose of pembrolizumab. Administration of killed vaccines is allowed.
  • Has a known history of (HIV) (HIV 1/2 antibodies).
  • Has known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected).
  • Has an active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Subjects with vitiligo or resolved childhood asthma/atopy would be exception to this rule. Subjects that require inhaled steroid or local steroid injections will not be excluded from the study. Subjects with hypothyroidism not from autoimmune disease and stable on hormone replacement will not be excluded from the study. Note: Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has had an allogenic tissue / solid organ transplant.
  • Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit (Visit 1) through 120 days after the last dose of study treatment.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Olaparib

    This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.

    Drug: Pembrolizumab · Drug: Olaparib

Interventions

  • Pembrolizumab IV solution administered on Day 1 of each 3-week cycle

    Also known as: Keytruda, MK-3475

  • Olaparib administered orally twice a day

    Also known as: Lynparza

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Per RECIST1.1

    Defined as complete or partial response per RECIST 1.1 criteria with assessment every 9 weeks during the first year and while on the study drug, and every 12 weeks thereafter. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions;; Overall Response (OR) = CR + PR

    Time frame: Up to 2 Years

Secondary outcomes

  1. Progression Free Survival (PFS), Per RECIST 1.1

    As measured by RECIST 1.1, in patients progressing after 1st line therapy

    Time frame: Up to 2 years

  2. Overall Survival (OS)

    Calculated in days from the start of treatment to the date of death from any cause

    Time frame: Up to 2 years

  3. Clinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.1

    As measured by RECIST 1.1, in patients progressing after 1st line therapy

    Time frame: Up to 2 years

  4. Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1

    As measured by RECIST 1.1, in patients progressing after 1st line therapy

    Time frame: Up to 2 years

07

Results

Posted May 29, 2025

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + Olaparib
Started14
Completed11
Not completed3
Withdrew: Death2
Withdrew: Disease progression and was taken off study. only received pembrolizumab & is not evaluable.1

Outcome measures

PrimaryOverall Response Rate (ORR) Per RECIST1.1

Defined as complete or partial response per RECIST 1.1 criteria with assessment every 9 weeks during the first year and while on the study drug, and every 12 weeks thereafter. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions;; Overall Response (OR) = CR + PR

Time frame:
Up to 2 Years
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) Per RECIST1.1
ParticipantsPembrolizumab + Olaparib
Overall Response Rate (ORR) Per RECIST1.13
SecondaryProgression Free Survival (PFS), Per RECIST 1.1

As measured by RECIST 1.1, in patients progressing after 1st line therapy

Time frame:
Up to 2 years
Reported as:
Mean · days
Progression Free Survival (PFS), Per RECIST 1.1
daysPembrolizumab + Olaparib
Progression Free Survival (PFS), Per RECIST 1.1158.08 ± 185.94
SecondaryOverall Survival (OS)

Calculated in days from the start of treatment to the date of death from any cause

Time frame:
Up to 2 years
Reported as:
Mean · days
Overall Survival (OS)
daysPembrolizumab + Olaparib
Overall Survival (OS)327.33 ± 227.69
SecondaryClinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.1

As measured by RECIST 1.1, in patients progressing after 1st line therapy

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Clinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.1
ParticipantsPembrolizumab + Olaparib
Clinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.13
SecondaryDuration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1

As measured by RECIST 1.1, in patients progressing after 1st line therapy

Time frame:
Up to 2 years
Reported as:
Mean · days
Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1
daysPembrolizumab + Olaparib
Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1262.00 ± 299.42

Adverse events

Collected over Adverse events are collected for up to two years of total study participation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Olaparib6/12 (50%)3/12 (25%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventPembrolizumab + Olaparib
SepsisInfections and infestations2/12
Back PainMusculoskeletal and connective tissue disorders1/12
Neck PainMusculoskeletal and connective tissue disorders1/12
PneumonitisRespiratory, thoracic and mediastinal disorders1/12
FallInjury, poisoning and procedural complications1/12
Periodontal diseaseGastrointestinal disorders1/12
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPembrolizumab + Olaparib
NauseaGastrointestinal disorders8/12
Anemia HemoglobinBlood and lymphatic system disorders6/12
DiarrheaGastrointestinal disorders5/12
FatigueGeneral disorders5/12
ConstipationGastrointestinal disorders4/12
HeadacheNervous system disorders4/12
AnorexiaMetabolism and nutrition disorders3/12
Back PainMusculoskeletal and connective tissue disorders3/12
VomitingGastrointestinal disorders3/12
BloatingGastrointestinal disorders2/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pembrolizumab + Olaparib
<=18 years0
Between 18 and 65 years7
>=65 years4
Age, Continuous
Age, Continuous(years)Pembrolizumab + Olaparib
Mean54.45455 ± 13.09476
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Olaparib
Female11
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Olaparib
Hispanic or Latino0
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Olaparib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White8
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Pembrolizumab + Olaparib
United States11
08

Study locations

1 site
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Oct 2024, 84 months.

Results were first posted in May 2025, 7 months after primary completion.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 84 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2017
First posted
Jan 19, 2017
StartActual
Sep 10, 2017
Primary completionActual
Oct 8, 2024
CompletionActual
Nov 21, 2025
Results first posted
May 29, 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 28, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionOverall Response Rate (ORR) Per RECIST1.1: how it is measured was reworded
Oct 28, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionOverall Survival (OS): how it is measured was reworded
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Posted results revised
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionOverall Response Rate (ORR) Per RECIST1.1: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionOverall Survival (OS): how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03025035
Lead sponsor
Yuan Yuan
Responsible party
Yuan Yuan (Director, Breast Oncology, Cedars-Sinai Medical Center) — Sponsor-investigator
First posted
Jan 19, 2017
Start date
Sep 10, 2017
Primary completion
Oct 8, 2024
Completion
Nov 21, 2025
Results posted
May 29, 2025
Last update
Oct 28, 2026

Study contacts

Yuan Yuan, MD
principal investigator · Cedars-Sinal Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Olaparib

Start the discussion